Research Article

Identification of genetic polymorphisms in DNA repair xeroderma pigmentosum group D gene and its association with head and neck cancer susceptibility in rural Indian population: a hospital based case-control study from south-western Maharashtra, India

Kailas D. Datkhile1*, Rohit D. Vhaval1, Madhavi N. Patil1, Tejasvi S. Khamkar1, Pratik P. Durgawale1, Pandurang G. Chougule2, Neville Tata2, Ritwij Patankar2, Anand Gudur3, Satish V. Kakade3

1Molecular and Genetic Laboratory, Krishna Institute of Medical Sciences, Karad, Satara, 415539, Maharashtra, India
2Department of Surgery, Krishna Institute of Medical Sciences, Karad, Satara, 415539, Maharashtra, India
3Department of Preventive and Social Medicine, Krishna Institute of Medical Sciences, Karad, Satara, 415539, Maharashtra, India

Received: 17 March 2016
Revised: 18 March 2016
Accepted: 22 April 2016

*Correspondence:
Dr. Kailas D. Datkhile,
E-mail: kddatkhile@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Smoking and alcohol related head and neck cancer is a major concern of health risk in developing countries, such as India. In this study, we aimed to determine the frequency of polymorphisms in DNA repair gene, xeroderma pigmentosum complementation group D (XPD) at codon (cd) 156, cd199, cd320, cd751 in patients of oral cancer from South-Western Maharashtra, India and to evaluate their association with oral cancer development.

Methods: We used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to analyze XPD gene polymorphisms in 320 patients with oral cancer and in 400 age and sex matched disease controls.

Results: There was no significant difference in the genotype distribution between oral cancer patients and controls for each polymorphism (p>0.05) except XPD199. The result from our study showed that allele frequencies of selected genes were not statistically different between the groups for XPD Arg156, XPD Asn320, XPD Gln751. XPDMet199 (OR=29.44; 95% CI= (18.47-46.92); p≤0.0001) genotypes significantly increased the risk of head and neck cancer.

Conclusions: This study indicates that polymorphisms in cd199 of XPD gene could play a role in modifying genetic susceptibility of individual to head and neck cancer in Maharashtra patients. Thus, the case-control study suggest that selected DNA repair genes represent genetic determinants in oral carcinogenesis along with other risk factors in the rural Indian population.

Keywords: Genetic polymorphisms, XPD, Cancer risk, Genotyping, PCR-RFLP

INTRODUCTION

Oral cancer is the fifth most common type of cancer worldwide and second in the developing world.1,2 In the Indian subcontinent head and neck cancer (HNC) is the frequent malignancy, accounting up to 40–50% of all malignant cancers.3 The incidence of HNC has significantly increased in the past 20 years and has become the fourth most common cause of cancer among men and third most common cancer among women in

DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20161749
India. Among the major documented risk factors associated with HNC are tobacco smoking’s, alcohol consumption followed by diet, oral health or exposure to environmental carcinogens. Carcinogenic molecules from these carcinogens are known to cause oxidative DNA damage to epithelial cells, but such damage is known to be corrected by some DNA repair mechanisms. It is also believed that along with the environmental factors, the host factors including individual’s genetic susceptibility related to genetic polymorphisms of various genes including those involved in DNA repair pathway is also likely to play a role in the development of oral cancer. Though the genetic factors are considered of great importance to cancer risk through the modulation of DNA repair but the genomic etiology of HNC is largely unknown.

There are three major pathways involved in DNA damage and repair which play a pivotal role in maintenance of genomic integrity such as base excision repair (BER), nucleotide excision repair (NER) and double strand break repair (DSBR). But it is not yet clear which DNA repair pathways or enzymes are most important for protection against HNC. The NER pathway is an important mechanism that repairs DNA damage which involved in the removal of variety of bulky DNA lesions such as ultra violet light induced pyrimidine dimer, other photoproducts, larger chemical adducts and crosslinks.

Human xeroderma pigmentosum complementation group D (XPD) is one of the major gene involved in NER pathway through recognition and repair of thymidine dimers. XPD have DNA helicase activity which participates in NER pathway and basal transcription through stabilizing the transcription factor complex TFIID. Hundreds of polymorphisms in DNA repair genes associated with cancer risk have been identified but their effects on repair function have not been well characterized.

Some of them are X-ray crosscomplementing group (XRCC), Xeroderma pigmentosum complementation group D (XPD), xeroderma pigmentosum complementation group C (XPC) and xeroderma pigmentosum complementation group G (XPG) which have been frequently studied and there is a growing body of evidence that polymorphisms of these genes may have some phenotypic significance. Previous studies on XPD suggested that XPD polymorphisms were associated with risk of skin cancer, breast cancer, gliomas, and bladder cancer in Caucasian, Americans, British and Chinese populations.

Few molecular epidemiologic studies have evaluated the association of HNC with functional genetic variants in the XPD genes, but in some of the studies the results are contradictory rather than convincing. Also, the earlier observations were not consistent in terms of their roles in oral cancer susceptibility and therefore the influence of the polymorphisms of XPD genes on DNA repair capacity is still unclear. It is also uncertain which DNA repair pathway genes may be more important for protection against head and neck cancer. In earlier studies we have shown that polymorphisms in BER pathway genes especially XRCC1, XRCC4, XRCC5 and XRCC7 plays an important role in susceptibility of head and neck cancer in rural population of south-western Maharashtra, India.

In continuation with this, we also hypothesized that the inherited polymorphisms of NER pathway genes may contribute to genetic susceptibility to head and neck cancer. To test this hypothesis we also focused on different genetic polymorphisms of NER pathway genes especially XPD to evaluate their role in head and neck cancer if any.

We performed a hospital based case-control study using a polymerase chain reaction based restriction fragment length polymorphism (PCR-RFLP) assay to genotype the polymorphisms of selected DNA repair genes in relation to head and neck cancer susceptibility in a rural population of south-western Maharashtra from India. We determined the genotypic frequency of polymorphisms of the (A) XPD C22541A at codon 156 of the exon 6 (B) XPD C23047G at codon 199 of the exon 8 (C) XPD G23592A at codon 312 in the exon 10 and (D) XPD A35931C at codon 751 in the exon 23 using the restriction enzymes TfiI, DpnII, Styl and PstI respectively. Multivariate logistic regression analysis was performed to calculate adjusted odds ratio (OR) and 95% confidence intervals (CIs).

**METHODS**

This study was a hospital based, case-control study conducted in rural areas of south-western Maharashtra from India. Study participants included 320 patients, newly diagnosed with head and neck cancer and 400 healthy, cancer free, age and sex matched individuals were selected as controls living in the same residential areas as the cases. All cases ranged in age from 30 - 80 years (Mean±SD) 54.42±12.95 were recruited immediately after being diagnosed. Trained interviewers used a structured questionnaire to collect personal interview data from the participants regarding demographic factors and known risk factors including occupational history, dietary habits, smoking and drinking status and individual family history of diseases, including cancer.

**Genomic DNA isolation from whole blood**

Five milliliter (mL) of whole blood from patients and normal age matched controls was collected in sterile purple top vacutainer after receiving informed consent. Genomic DNA extraction was carried out from the peripheral blood sample using Purelink genomic DNA extraction and purification Kit (Invitrogen, Life technologies) following the manufacturer’s instructions.
Genotyping assays

Genotyping of XPD gene were performed by PCR-RFLP methods with appropriate primer sets (Table 1). The primers were designed to amplify the regions of DNA that contain polymorphic sites of interest: (A) XPD C22541A codon 156 in the exon 6 (B) XPD C23047G at codon 199 of the exon 8 (C) XPD G23592A at codon 312 in the exon 10 and (D) XPD A35931C at codon 751 in the exon 23.

### Table 1. Details of PCR and RFLP procedures and expected products of XPD genes.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primers Forward/Reverse</th>
<th>PCR conditions</th>
<th>PCR Product</th>
<th>Restriction enzyme</th>
<th>Restriction products</th>
</tr>
</thead>
<tbody>
<tr>
<td>XPD C22541A Arg156Arg codon 156 Ex-6</td>
<td>5'- tgt ggg atc gct gca cga tct ct -3' 5'- cca tgg gca tca aat tcc tgg ga -3'</td>
<td>95°C: 5 min, 30 cycles of 95°C: 30 sec, 60°C: 30 sec, 72°C: 30 sec, 72°C: 5 min</td>
<td>644 bp</td>
<td>1U of TfiI</td>
<td>C/C: 587bp, 57bp C/A: 587bp, 474bp, 113bp, 57bp A/A: 474bp, 113 bp, 57bp</td>
</tr>
<tr>
<td>XPD C23047G Ile199Met codon199 Ex-8</td>
<td>5'- ctc tgt ggg gtc cgt atc tgt ggc tca ccc tgc agc act tcc c - 3'</td>
<td>95°C: 5 min, 35 cycles of 95°C: 30 sec, 55°C: 30 sec, 72°C: 30 sec, 72°C: 5 min</td>
<td>357 bp</td>
<td>1U DpnII</td>
<td>Control cut: 357bp Ile/Ile: 176bp, 73bp Ile/Met: 243bp,176bp,73bp Met/Met: 243bp</td>
</tr>
<tr>
<td>XPD G23591A Asp312Asn codon312 Ex-10</td>
<td>5'-ctg tgt ggt ggc tgt atc tgt ggg tca ccc tgc agc act tcc c - 3' 5'-taa tat cgg ggc tca ccc tgc agc act tcc c - 3'</td>
<td>95°C: 5 min, 35 cycles of 95°C: 30 sec, 62°C: 45 sec, 72°C: 30 sec, 72°C: 5 min</td>
<td>751 bp</td>
<td>1U of StyI</td>
<td>Asp/Asp: 507bp, 244bp Asp/Asn: 507bp, 244bp, 33bp Asn/Asn: 474bp, 244bp 33bp</td>
</tr>
<tr>
<td>XPD A35931C Lys751Gln codon751 Ex-23</td>
<td>5'-caag gta cag cca ggt cct ag -3' 5'- cct tcc etc atc tgg aat gc -3'</td>
<td>95°C: 5 min, 30 cycles of 95°C: 30 sec, 55°C: 30 sec, 72°C: 30 sec, 72°C: 5 min</td>
<td>436 bp</td>
<td>2U PstI</td>
<td>Lys/Lys (A/A): 290bp, 146 bp Lys/Gln (A/C): 290bp, 227bp, 146bp, 63bp Gln/Gln (C/C) 227bp, 146bp, 63bp</td>
</tr>
</tbody>
</table>

The PCR amplification were carried out separately under different conditions in 20 micro liter (µL) reaction mixtures containing 1X PCR buffer (10 mili molar (mM) Tris-HCl (pH 9.0), 50 mM KCl 1.5 mM MgCl2, 0.01% gelatin), 0.2 mM each dNTP, 10 picomole (pmol) of each primer listed in Table-1, 1U Taq DNA polymerase (GeNei, Merck Bioscience) and 100 nanogram (ng) of purified genomic DNA template. The reaction mixtures were subjected to PCR amplification with a Master Cycler Gradient PCR (Eppendorf). After performing PCR programme for each of the reactions, the PCR products were analyzed by agarose gel electrophoresis in Tris-Acetate-EDTA (TAE) buffer.

The agarose gels were stained with ethidium bromide (10 mg/mL) and visualized under UV Transilluminator and photographed in gel documentation system (BioRad Laboratories). After confirmation of DNA amplification, each PCR product was digested with an appropriate restriction enzyme as shown in Table-1 for genotyping. Ten µL of the PCR products were digested at 37°C overnight with specific restriction enzymes in 20 µL reaction mixtures containing buffer supplied with each restriction enzyme. After the overnight incubation, digestion products were then separated on a 2-3% low EEO agarose (GeNei) gel at 100Volts for 30 min stained with ethidium bromide and photographed with gel documentation system.

### Statistical analysis

All statistical analyses were performed using SPSS 11.5 for windows software. The associations between the XPD genotypes and risk of HNC with or without smoking and drinking history were studied using odds ratio (OR). Both the univariate and multivariate logistic regression analyses were employed to calculate the adjusted odds ratios (ORs) and 95% confidence intervals (CIs) to determine the cancer risk associated with genotypes.

### RESULTS

During the study period, 320 patients with oral cancer met the eligibility criteria for this study and 400 controls were selected to match these cases. The characteristics of age and sex matched cases and controls are presented in...
Table 2. The (Mean±SD) age in years was 54.42±12.95 for the cases and 52.84±12.94 (P<0.05) for the controls, however there was no significant difference in mean age between cases and controls. Also, there was no significant difference in males of cases (62.50%) and of controls (65.00 %). There were more smokers (78.13%) and drinkers (68.75 %) in cases as compared to controls (20.0 % and 12.50.00) respectively enrolled in this study.

![Table 2: Distribution comparisons of selected demographic characteristics of head and neck cancer cases and healthy controls from rural areas of Maharashtra in India.](image)

Association of polymorphisms in XPD gene and smoking and drinking status in cases of HNC and age and sex matched controls

XPD gene comprises 23 exons and spans ~19.20 kb on chromosome 19q13.3. XPD gene coding regions have been identified in six major SNP sites corresponding to nucleotide changes were C22541A, C23047G, C23051T, G23591A, C35326T, A35931C corresponding to codons 156, 199, 201, 312, 711, 751 respectively. We investigated the distribution and association between the previously described polymorphisms of cd156, cd199, cd312 and cd751 of XPD genes in relation with tobacco, alcohol consumption from rural Maharashtrian population.

(A) XPD C22541A codon 156 exon 6

The amplification of XPD codon 156 resulted in the product of 644 bp. The TfiI enzyme was used to detect the XPD C22541A at codon 156 of exon 6. The PCR amplified products upon treatment with TfiI yielded wild-type (22541C) alleles of 587, 57bp fragments, and the polymorphic (A) allele produces 3 fragments of 474, 113 and 57 bp (Figure 1A). The frequency of XPD 22541 CC homozygotes was 53.75% in cases and 59.50 % in controls whereas the frequency of 22541A allele was lower but not significantly in the cases (13.75 %) than in the controls (10.0 %). The frequency of XPD22541 CA heterozygotes was 32.50 % in cases and 30.50 % in controls (Table 3). Thus, the C→A polymorphism in
Table 3: The genotype frequencies of XPD gene variants in untreated head and neck cancer patients and controls.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Genotype</th>
<th>Cases (n=320) (%)</th>
<th>Control (n=400) (%)</th>
<th>Odds' Ratio (OR) (95% CI)</th>
<th>P value</th>
<th>Adjusted Odds Ratio (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>XPD Arg156Arg</td>
<td>Codon 156 Ex-6 C22541A</td>
<td>CC/CC</td>
<td>172 (53.75)</td>
<td>238 (59.50)</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CC/AA</td>
<td>104 (32.50)</td>
<td>122 (30.50)</td>
<td>1.18 (0.85-1.63)</td>
<td>0.32</td>
<td>7.15 (3.72-13.740)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AA/AA</td>
<td>44 (13.75)</td>
<td>40 (10.00)</td>
<td>1.52 (0.95-2.43)</td>
<td>0.08</td>
<td>9.12(4.14-(20.07)</td>
</tr>
<tr>
<td>XPD Ile199Met</td>
<td>Codon 199 Ex-8 C23047G</td>
<td>CC/CC</td>
<td>40 (12.50)</td>
<td>254 (63.50)</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CC/GG</td>
<td>76 (23.75)</td>
<td>102 (25.50)</td>
<td>4.73 (3.02-7.39)</td>
<td>&lt;0.0001*</td>
<td>0.049(0.024-0.097)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GG/GG</td>
<td>204 (63.75)</td>
<td>44 (11.00)</td>
<td>29.44 (18.46-46.93)</td>
<td>&lt;0.0001*</td>
<td>0.007(0.003-0.014)</td>
</tr>
<tr>
<td>XPD Asp312Asn</td>
<td>Codon312 Ex-10 C23591A</td>
<td>GG/GG</td>
<td>166 (51.88)</td>
<td>224 (56.00)</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>GG/AA</td>
<td>86 (26.87)</td>
<td>96 (24.00)</td>
<td>1.31 (0.92-1.87)</td>
<td>0.29</td>
<td>0.96 (0.59-1.55)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AA/AA</td>
<td>68 (21.25)</td>
<td>80 (20.00)</td>
<td>1.14 (0.78-1.67)</td>
<td>0.48</td>
<td>0.79 (0.47-1.31)</td>
</tr>
<tr>
<td>XPD Lys751Gln</td>
<td>Codon751 Ex-23 A35931C</td>
<td>GG/AA+</td>
<td>154 (48.12)</td>
<td>176 (44.00)</td>
<td>1.18 (0.87-1.55)</td>
<td>0.26</td>
<td>0.87 (0.604-1.26)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AA/AA</td>
<td>168 (52.50)</td>
<td>260 (65.00)</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AA/CC</td>
<td>100 (31.25)</td>
<td>80 (20.00)</td>
<td>1.93 (1.36-2.75)</td>
<td>&lt;0.001</td>
<td>0.39 (0.24-0.63)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CC/CC</td>
<td>52 (16.25)</td>
<td>60 (15.00)</td>
<td>1.34 (0.88-2.03)</td>
<td>0.16</td>
<td>0.89 (0.50-1.52)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AA/CC+</td>
<td>152 (47.50)</td>
<td>140 (35.00)</td>
<td>1.68 (1.24-2.26)</td>
<td>&lt;0.001</td>
<td>0.55 (0.38-0.81)</td>
</tr>
</tbody>
</table>

*: Indicates significant Odds Ratio (p<0.05), p value determined based on χ2

(A) XPD C22541A Codon 156 Ex-6 by TfiI, (Lane 1: 100bp DNA ladder, lane 2: Uncut PCR product, lane 3: CC genotype, lane 4: CA genotype, lane 5: AA genotype (B) XPD Ile199Met codon199 Ex-8 by DpnII, (Lane 1: 100 bp DNA ladder, lane 2: Control cut , lane 3: CC genotype, lane 4: CG genotype, lane 5: GT genotype and (D) XPD A35931C Lys751Gln Ex-23 by PstI (Lane 1: 100 bp DNA ladder, lane 2: Uncut PCR product, lane 3: AA genotype, lane 4: AC genotype, lane 5: CC genotype.

Figure 1: Representative agarose gel image showing nucleotide polymorphism by PCR-RFLP.

(B) XPD C23047G codon199 exon 8

The C—G distribution in codon 199 of the exon 8 results in Ile → Met substitution. The frequency of XPD 23047 CC wild type homozygotes was 12.50 % in cases and 63.50 % in controls whereas XPD23047GG variant homozygotes were 63.75 % in cases and 11.0 % in controls.

The frequency of XPD23047GG heterozygotes was 23.75% in cases and 25.50% in controls (Table 3). The frequency of the XPD 23047G allele was significantly higher in cases (0.63) than in controls (0.11).

Compared to 23047CC genotype, the variant genotype 23047GG genotype was associated with oral cancer risk (OR=29.44; 95% CI= (18.46-46.93) of HNC. Compared with combined group of 23047CC + 23047CG genotypes the 23047GG genotype remained associated with increased risk of HNC.

The XPD 23047GG variant genotype was more frequent in cases (63.75%) than in controls whereas the XPD23047CC genotypes were significantly lower in cases (12.50 %) than in controls (63.50%). The 23047 variants of the DNA repair gene XPD are extremely high and contribute significantly to the risk of HNC in the rural population of south western Maharashtra.
(C) XPD G23592A codon 312 exon 10

Table-3 displays the distribution of genotypes and frequency of alleles of the G23592A polymorphisms in patients with head and neck cancer and controls. All distributions of genotypes and alleles were in Hardy-Weinberg equilibrium. We did not find any significant difference in genotype or allele frequencies in patients with cancer and controls. The G→A polymorphism in codon 312 of the exon 10 results in Asp→Asn substitution in an evolutionary conserved region. The frequency of XPD 23592GG homozygotes was 51.88 % in cases and 56.00 % in controls whereas 23592AA homozygote was 21.25 % in cases and 20.0 % in controls. The frequency of 23592GA heterozygotes was 26.87% in cases and 24.00% in controls (Table-3). This allele frequency in the controls was similar to previously reported studies.

Table 4: Stratification analysis of the demographic factors including age, tobacco smoking and alcohol drinking and distribution of genotypes with odds ratio of the XPD genes in the patients with head and neck cancer and the control group from rural population of south-western Maharashtra, India.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Genotype</th>
<th>Demographic factors</th>
<th>Sex (Cases/Control)</th>
<th>Smoking status (Cases/Control)</th>
<th>Drinking status (Cases/Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Male N=200/260</td>
<td>Female N=120/140</td>
<td>Smokers N=253/80</td>
</tr>
<tr>
<td>XPD Arg156Arg codon 156 Ex-6 C22541A</td>
<td>CC/CC</td>
<td>Age ≤50 N=122/150</td>
<td>68/88 104/150</td>
<td>105/150 67/88</td>
<td>140/51 32/187</td>
</tr>
<tr>
<td></td>
<td>CC/AA+AA/AA</td>
<td>&gt;50 N=198/250</td>
<td>95/13 94/100</td>
<td>53/52 113/29</td>
<td>35/133 98/19</td>
</tr>
<tr>
<td></td>
<td>OR</td>
<td>(95% CI)</td>
<td>1.12 (0.69-1.82)</td>
<td>1.35 (0.73-1.97)</td>
<td>1.33 (0.81-2.20)</td>
</tr>
<tr>
<td></td>
<td>P value</td>
<td></td>
<td>&lt;0.00001 0.25</td>
<td>0.18 0.11</td>
<td>0.40 0.10</td>
</tr>
<tr>
<td>XPD Ile199Met codon 199 Ex-8 C23047G</td>
<td>CC/CC</td>
<td>Age ≤50 N=122/150</td>
<td>22/81 18/173</td>
<td>24/169 16/85</td>
<td>25/53 15/201</td>
</tr>
<tr>
<td></td>
<td>CC/CG+ GG/GG</td>
<td>&gt;50 N=198/250</td>
<td>176/91 104/55</td>
<td>22/287 52/119</td>
<td>190/19 90/127</td>
</tr>
<tr>
<td></td>
<td>OR</td>
<td>(95% CI)</td>
<td>3.33 (2.37-4.86)</td>
<td>5.33 (3.04-9.36)</td>
<td>5.10 (3.15-8.30)</td>
</tr>
<tr>
<td></td>
<td>P value</td>
<td></td>
<td>&lt;0.00001 &lt;0.0001</td>
<td>&lt;0.0001 &lt;0.0001</td>
<td>&lt;0.0001 &lt;0.0001</td>
</tr>
<tr>
<td>XPD Asp312Asn codon 312 Ex-10 G23591A</td>
<td>GG/GG</td>
<td>Age ≤50 N=122/150</td>
<td>63/86 103/138</td>
<td>126/150 74/74</td>
<td>129/42 173/182</td>
</tr>
<tr>
<td></td>
<td>OR</td>
<td>(95% CI)</td>
<td>1.23 (0.76-2.00)</td>
<td>1.13 (0.78-1.65)</td>
<td>1.16 (0.81-1.66)</td>
</tr>
<tr>
<td></td>
<td>P value</td>
<td></td>
<td>0.38 0.50</td>
<td>0.39 0.15</td>
<td>0.81 0.80</td>
</tr>
<tr>
<td>XPD Lys751Gl codon 751 Ex-23 A35931C</td>
<td>AA/AA</td>
<td>Age ≤50 N=122/150</td>
<td>62/83 106/177</td>
<td>110/168 58/92</td>
<td>130/54 38/206</td>
</tr>
<tr>
<td></td>
<td>AA/AC+ CC/CC</td>
<td>&gt;50 N=198/250</td>
<td>60/67 92/73</td>
<td>100/92 62/48</td>
<td>123/26 29/114</td>
</tr>
<tr>
<td></td>
<td>OR</td>
<td>(95% CI)</td>
<td>1.19 (0.74-1.93)</td>
<td>2.10 (1.42-3.10)</td>
<td>1.66 (1.14-2.40)</td>
</tr>
<tr>
<td></td>
<td>P value</td>
<td></td>
<td>0.45 0.002</td>
<td>0.007 0.004</td>
<td>0.01 0.23</td>
</tr>
</tbody>
</table>

(D) XPD A35931C codon 751 exon23

The amplification of XPD codon 751 resulted in the product of 436 bp. The PstI enzyme was used to detect the XPD A35931C at codon 751 of exon 23. The PCR amplified products upon treatment with PstI yielded wild-type (35931A) alleles of 290, 146bp fragments, and the polymorphic (C) allele produces 3 fragments of 227, 146 and 63 bp (Figure 1D). The A→C polymorphism in exon 23 at nucleotide position 35931 gives rise to the amino acid substitution Lys→Gln in the codon 751. Table-3 displays the distribution of genotypes and frequency of alleles of the A35931C polymorphisms in patients with head and neck cancer and controls. The distribution of the genotypes in control group was in Hardy-Weinberg equilibrium.
equilibrium. The frequency of the XPD 35931C allele was not significantly higher in the cases (16.25%) than in the controls (15.00%) which are at the lower end of the previously reported allele frequencies.

DISCUSSION

In this hospital based case-control study we investigated the relationship between newly reported genotype polymorphisms of DNA repair genes especially involved in NER pathway and the elevated risk for oral cancer particularly in the users of tobacco and alcohol from the rural areas of south-western Maharashtrita. We determined the genotypic frequency of polymorphisms of the NER DNA repair pathway (A) XPD C22541A at codon 156 of the exon 6 (B) XPD C23047G at codon 199 of the exon 8 (C) XPD G23592A at codon 312 in the exon 10 and (D) XPD A35931C at codon 751 in the exon 23. To evaluate the association XPD variants and risk of HNC crude and adjusted ORs and their 95% CIs were calculated using both homozygous genotypes or combined with their respective heterozygous genotypes as the reference groups. Comparable wild type genotype frequencies of XPD codon 156, codon 312, and codon 751 showed wide distribution in the Maharashtrian population in controls as well as HNC cases.

The frequency of allele of the XPD polymorphisms at 22541(C-A), 23591 (G-A), 35931 (A-C) did not show much variation with the oral cancer risk in south-western Maharashtrian population. Also, when we conducted a case-control study to investigate the relationship between the polymorphisms of XPD and the risk of oral cancer in a south-western Maharashtrian population, we find association between the XPD codon 199 at Ile 199 Met polymorphism and smoking and drinking related oral cancer. Previously, Xing D et al reported that the frequencies of Asn allele of XPD 312 and the Gln allele of XPD 751 are 0.06 and 0.07 in hospital based case control study whereas they were reported to be 0.19 and 0.33 respectively by Spitz MR et al. In our study the frequency of Met allele XPD 199 was 0.64 that of XPD 156 allele Arg was 0.13 and that of XPD 312 Asn allele was 0.21 and frequency of XPD 751 allele Gln was 0.16 which were to some extent different from other reports.

The polymorphism in DNA repair genes has been extensively investigated for its associations with cancer risk and the results were conflicting in different types of cancer or different populations. The investigations into the relationship between polymorphisms in DNA repair genes and susceptibility to environmental cancer have not yet produced consistent results. However, there is an inconsistency most likely due to the complexity of the biological process and of molecular epidemiological investigations.

Several molecular epidemiological studies have investigated the association between genetic polymorphisms in XPD and susceptibility to several kinds of cancers including skin cancer, breast cancer, gliomas and bladder cancer among different ethnic including Caucasian, Americans, British and Chinese populations. Whereas few other studies failed to find positive evidence for XPD polymorphisms in squamous cell carcinoma of the head and neck (SCCHN) or melanoma. Very few studies from Northern and Southern India have reported the genetic polymorphisms in the DNA repair genes with respect to a variety of cancer risks including prostate, breast, oral and esophageal cancers. However, very limited information is available on the association of genetic polymorphisms of DNA repair genes including NER pathway genes and their susceptibility to oral cancer from rural population of Maharashtra where the rate of tobacco and alcohol consumption is very high. Therefore in this study, we aimed to investigate the relationship between the development of oral cancer and genetic polymorphisms in XPD genes with respect to tobacco and alcohol exposure from a pool of unexplored rural Maharashtrian population. Such genotyping analysis of DNA repair genes will enhance our ability to identify those individuals most susceptible to tobacco and alcohol induced carcinogenesis in the rural population of south-western Maharashtra.

CONCLUSION

This study is the first time to report the combined effects of XPD gene polymorphisms on the risk of head and neck cancer in Maharashtrian population. Our results showed that the XPD gene at position 23047 of codon 199 of exon 8 polymorphism which could be associated with the risk of oral cancer. This analysis of correlation of DNA repair genes will enhance our ability to identify those individuals most susceptible to tobacco and alcohol induced carcinogenesis in the rural population of south-western Maharashtra.

ACKNOWLEDGEMENTS

Authors would like to acknowledge Dr. R K. Ayachit, Director, Health Sciences of Krishna Institute of Medical Sciences for guidance and support to carry out this research. The experimental assistance of Mr. Santosh Jadhav is duly acknowledged.

Funding: Intramural funding by Krishna Institute of Medical Sciences
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES


30. Mohrenweiser HW, Wilson DM, Jones IM. Challenges and complexities in estimating both the


